<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290873</url>
  </required_header>
  <id_info>
    <org_study_id>CNS7056-006</org_study_id>
    <nct_id>NCT02290873</nct_id>
  </id_info>
  <brief_title>A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients</brief_title>
  <official_title>A Prospective, Double-blind, Randomized, Placebo and Active Controlled, Multi-center, Parallel Group Study Comparing Remimazolam to Placebo, With an Additional Open-label Arm For Midazolam, in Patients Undergoing a Colonoscopy for Diagnostic or Therapeutic Reasons.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, double-blind, randomized, placebo and active controlled, multi-center,
      parallel group study comparing remimazolam to placebo, with an additional open-label arm for
      midazolam, in patients undergoing a colonoscopy for diagnostic or therapeutic reasons.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2015</start_date>
  <completion_date type="Actual">April 19, 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of Procedure</measure>
    <time_frame>From start to end of colonoscopy</time_frame>
    <description>Measured by completion of colonoscopy, no requirement for an alternative sedative and no requirement for more than 5 top-ups of study medication within any 15 minute period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to start of procedure</measure>
    <time_frame>From first dose of study drug until insertion of the colonoscope</time_frame>
    <description>The time to the start of the procedure after administration of the first dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak sedation</measure>
    <time_frame>From first dose of study drug until the lowest level of sedation, which has occurred during the colonoscopy procedure.</time_frame>
    <description>The time from the first dose of the study drug to the lowest level of sedation occurring during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ready for discharge</measure>
    <time_frame>From the end of the colonoscopy and after the last dose of study drug, until discharge, expected to be the same day.</time_frame>
    <description>The time after the end of colonoscopy procedure (colonoscope out) and after the last injection of study drug (defined as ability to walk unassisted).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fully alert</measure>
    <time_frame>From the last dose of study drug, until the patient has recovered to fully alert. Expected to be the same day.</time_frame>
    <description>The time to fully alert (time to first of three consecutive Modified Observer's Assessment of Alertness/Sedation [MOAA/S] scores of 5 after the end of colonoscopy procedure [colonoscope out] and after the last injection of study drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>From first dose of study drug until Day 4, or resolution of any ongoing adverse events.</time_frame>
    <description>The number of patients who experience any untoward medical occurrence in a clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">461</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>Remimazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo iv for sedation induction and maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Remimazolam</arm_group_label>
    <other_name>CNS7056</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>For induction of maintenance and sedation</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients, aged ≥18, scheduled to undergo a diagnostic or therapeutic
             colonoscopy (therapeutic procedures could include hemostasis, resection, ablation
             decompression, foreign body extraction, for example).

          -  American Society of Anesthesiologists Score 1 through 3

          -  Body mass index ≤40 kg/m2.

          -  For female patients with child-bearing potential, negative result of pregnancy test
             (serum or urine) as well as use of birth control during the study period (from the
             time of consent until all specified observations were completed).

          -  Patient voluntarily signed and dated an informed consent form that was approved by an
             Independent Review Board prior to the conduct of any study procedure.

          -  Patient was willing and able to comply with study requirements and return for a
             Follow-up Visit on Day 4 (+3/-1 days) after the colonoscopy.

        Exclusion Criteria:

          -  Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone,
             or a medical condition such that these agents were contraindicated.

          -  Chronic use of benzodiazepines for any indication (eg, insomnia, anxiety, spasticity).

          -  Chronic use of opioids for any indication.

          -  Female patients with a positive serum human chorionic gonadotropin pregnancy test at
             screening or baseline.

          -  Lactating female patients.

          -  Patients with positive drugs of abuse screen or a positive serum ethanol at baseline.

          -  Patient with a history of drug or ethanol abuse within the past 2 years.

          -  Patients in receipt of any investigational drug within 30 days or less than seven
             half-lives (whichever was longer) before screening, or scheduled to receive one during
             the study period.

          -  Participation in any previous clinical trial with remimazolam.

          -  Patients with an inability to communicate well in English with the investigator, or
             deemed unsuitable according to the investigator (in each case providing a reason).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas K Rex, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Grover Clinic, P.A</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners Inc</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Tidewater</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Douglas K. Rex, MD, MACG, Raj Bhandari, MD, Taddese Desta MD, Michael DeMicco MD, Cynthia Schaeffer MD, Kyle Etzkorn, Charles Barish MD, Ronald Pruitt MD, Brooks Cash MD, FACG, Daniel Quirk MD, Felix Tiongco MD, David Bernstein MD, FACG. REMIMAZOLAM IS A SAFE AND EFFECTIVE AGENT FOR SEDATION IN OUTPATIENT COLONOSCOPY: RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED TRIAL. Program No. . ACG 2016 Annual Scientific Meeting Abstracts. Las Vegas, NV: American College of Gastroenterology.</citation>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

